Hereditary Colorectal Cancer Treatment & Management

  • Author: Juan Carlos Munoz, MD; Chief Editor: Julian Katz, MD   more...
 
Updated: Oct 31, 2011
 

Surgical Care

Removal of the entire colon is the only way to completely prevent the development of colon cancer or to treat an existing cancer. Several different operations are currently available for treatment of hereditary nonpolyposis colorectal cancer (HNPCC).

The 3 most commonly performed operations are as follows:

  • Subtotal colectomy with ileorectal anastomosis
  • Total colectomy ileoanal pull-through (pouch procedure)
  • Total colectomy with ileostomy

Subtotal colectomy with ileorectal anastomosis and postsurgical rectal surveillance are recommended when colorectal cancer develops in patients with hereditary nonpolyposis colorectal cancer (HNPCC). This operation may be considered for prophylaxis in selected MMR gene mutation carriers (see Prophylactic Colectomy).

Subtotal colectomy with ileorectal anastomosis is preferred over segmental resection or hemicolectomy for HNPCC-associated cancers that arise proximal to the peritoneal reflection. Although total proctocolectomy with ileoanal anastomosis and total proctocolectomy with ileostomy eliminate the need for endoscopic surveillance, these procedures are generally reserved for patients with hereditary nonpolyposis colorectal cancer (HNPCC) who present with rectal cancers, primarily because of concerns about postoperative morbidity and quality of life.

Next

Postoperative Surveillance

Postoperative surveillance is indicated following curative resection in patients with hereditary nonpolyposis colorectal cancer (HNPCC) because of the high rates of metachronous cancers (estimated as high as 40% at 10 y and 72% at 40 y, depending on the length of colon remaining after surgery). Surveillance sigmoidoscopy is recommended every 1-2 years following subtotal colectomy or surveillance colonoscopy is recommended every 1-2 years following subtotal partial colectomy.

Evidence supporting this recommendation is derived from the aforementioned studies demonstrating an accelerated rate of malignant transformation in hereditary nonpolyposis colorectal cancer (HNPCC) and 2 postresection surveillance studies demonstrating a high rate of metachronous cancers within 2-5 years. In 1994, Lanspa et al identified 17 patients (8%) (among a cohort of 225 patients with HNPCC) who developed metachronous cancers within 5 years of resection (mean, 26.7 mo; range, 4-58.5 mo).[33] In a Danish study of 110 patients with HNPCC, 8 Dukes A or B cancers and 1 Dukes C cancer were detected within 2 years of negative examination findings.[34]

Table 5. Dukes classification. (Open Table in a new window)

StageTumorNodeMetastasisDukes
Stage 1T1N0M0Dukes A
T2N0M0
Stage IIT3N0M0Dukes B
T4N0M0
Stage IIIAny TN1M0Dukes C
Any TN2, N3Mo
Stage IVAny TAny NM1Dukes D

Measures for primary prevention of familial colorectal cancer are discussed below.

Previous
Next

Prophylactic Colectomy

Because of the excessive occurrence of both incident and metachronous colon cancers (MCC), prophylactic subtotal colectomy (SC) or total colectomy (TC) may be an alternative to surveillance colonoscopy for individuals with confirmed mutations. Opponents argue that, because of incomplete penetrance, 15-20% of these colectomies may be unnecessary and that patients undergoing prophylactic SC remain at risk of developing metachronous rectal cancers and extra colonic malignancies.

Syngal et al used a decision-analysis model to evaluate life expectancy and quality-adjusted life expectancy derived from surveillance colonoscopy compared with prophylactic surgery in patients aged 25 years who had a confirmed mutation.[35] The analysis showed that, although both approaches offer a modest survival benefit over no intervention, immediate TC and SC were superior to surveillance, with an expected gain in life expectancy of 15.6 years after immediate TC and 15.3 years after SC, as compared with 13.5 years for surveillance.[35] However, the incremental benefit of surgery compared with surveillance diminished with increasing age. Moreover, quality-of-life adjustments favored surveillance over surgery.[35]

In a prospective cohort study by Stupart et al, 60 patients with proven germline mismatch repair gene defect underwent a resection for adenocarcinoma of the colon with a curative intent. All patients were offered annual endoscopic surveillance. Of the 60 patients included in the study, 39 had TC as their initial surgery and 21 had SC. After 6 years of follow-up, metachronus colon cancer (MCC) occurred in 8 (21%) patients that had SC and in none of the patients that had TC (p=0.048). The overall survival of the 2 groups was similar (p=0.29). This study concluded that patients with HNPCC have a significant risk of MCC after SC. This is eliminated by performing TC as the primary operation.[36]

Because no evidence-based data support one approach over another, aggressive surveillance is generally preferred, except in select situations in which surveillance is not technically feasible or in patients with mutations who refuse colonoscopic surveillance but agree to sigmoidoscopic surveillance of the rectal remnant. Regardless, patients should be informed about the advantages and disadvantages of each approach and should be encouraged to participate in the decision-making process. In such cases, because of the high rate of metachronous cancers, the colonic remnant should be examined by sigmoidoscopy every 1-2 years.

Previous
Next

Prophylactic Hysterectomy and Bilateral Salpingo-oophorectomy

Women should consider undergoing an annual gynecologic examination, including endometrial screening with biopsy (vacuum curettage or Pipel biopsy should be considered). To help reduce the risk of endometrial and ovarian cancer, some experts recommend discussing prophylactic hysterectomy and bilateral salpingo-oophorectomy with women older than 50 years who have hereditary nonpolyposis colorectal cancer (HNPCC). Counseling should include a discussion of the psychosocial effects of prophylactic surgery and the long-term effects of prolonged estrogen replacement therapy.

Currently, the evidence is insufficient to recommend prophylactic hysterectomy and salpingo–oophorectomy to help reduce cancer risk in women who carry the MMR gene. The exception to this rule includes females with MSH6 mutations. Current evidence suggests a higher risk for developing endometrial cancer in these women, therefore, prophylactic hysterectomy is indicated.[20, 21] (See Table 3 in Other Tests section above).

Previous
Next

Chemoprevention

Observational studies of persons at average risk have suggested that the use of some medications and supplements (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], aspirin, estrogens, folic acid, calcium), as well as antioxidants (eg, beta carotene, vitamin C, vitamin E), may prevent the development of colorectal cancer. However, randomized controlled trials of the use of chemopreventive agents are limited, and only a few studies have specifically enrolled people with an inherited predisposition for colorectal cancer; therefore, the evidence has not convinced experts to recommend these medications and supplements specifically to prevent colorectal cancer in patients with hereditary nonpolyposis colorectal cancer (HNPCC).

NSAIDs

Randomized controlled trials have shown that NSAIDs (sulindac and celecoxib) induce regression of adenomas in patients with FAP.[37, 38, 39, 40] A considerable volume of preclinical data support the safety and efficacy of cyclooxygenase-2 (COX-2) inhibitors in patients with FAP; therefore, the US Food and Drug Administration (FDA) has approved the use of celecoxib as an adjunct for the management of colorectal adenomas in patients with FAP. The value of COX-2 inhibitors in the sporadic adenoma population is not known.

Studies have shown that COX-2 expression occurs in patients with colorectal adenomas and cancers. However, the expression may not be as pronounced in colorectal adenomas and cancers in hereditary nonpolyposis colorectal cancer (HNPCC) as it is in FAP sporadic colorectal cancer.

Polymorphisms in drug-metabolizing genes may contribute to varied responses to NSAIDs. For example, flavin monooxygenase 3 (FMO3) may reduce the catabolism of sulindac, resulting in an increased efficacy in the prevention of polyps in persons with FAP. NSAIDs carry a small risk of bleeding complications, such as stroke and upper GI ulceration and bleeding, which weighs against possible benefits.

Aspirin

Prospective studies have demonstrated a significant reduction in colorectal cancers in healthcare workers who regularly used aspirin.[41] In 2011, the first randomized controlled trial into the effect of aspirin on cancer outcomes found that taking aspirin reduces the long-term risk of bowel cancer in people with a family history of the disease by 60%. The British trial, partly funded by Bayer, studied 861 people with Lynch Syndrome who took 600 mg of aspirin per day for 2 years. At a mean follow-up of 55.7 months, 18 of 427 patients randomly assigned to aspirin developed colorectal cancer compared to 30 of 434 patients assigned to aspirin placebo. Further study is needed to determine ideal dose and duration for different groups of people.[78]

Prior to the CAPP2 study, randomized controlled trials had shown reduced risk of adenomas but none had used prevention of colorectal cancer as a primary endpoint. A randomized, double-blind, placebo-controlled trial in patients with a personal history of colon adenomas demonstrated a modest but statistically significant reduction in the incidence of colonic adenomas with daily aspirin use. In a double-blind placebo study, daily aspirin use was also associated with reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.

Folic acid

In one observational study, the use of folic acid supplements for more than 15 years was associated with a 75% lower rate of colorectal cancer (relative risk [RR] of 0.25; 95% confidence interval [CI], 0.13–0.51).[42, 43] This study was performed in women with a family history of colon cancer. One hypothesis holds that, because folate is required for DNA synthesis, suboptimal amounts may cause abnormalities in DNA synthesis or repair.

Calcium

Researchers have suggested that calcium binds bile acids in the bowel lumen, inhibiting their carcinogenic effects.[44, 45, 46] A randomized controlled trial of calcium supplementation, with a daily intake of 1200 mg of elemental calcium for 4 years, reduced the risk of recurrent adenomas in presumably average-risk people with adenomas by 19% (adjusted risk ratio of 0.81; 95% CI, 0.67–0.99). This finding may not apply to people with a genetically increased risk of colorectal cancer.

Estrogens

Studies have demonstrated that estrogens are associated with a lower incidence of colorectal cancer; however, this information does not address those with a genetically increased risk of colorectal cancer.[47]

Previous
Next

Modifying Behavioral Risk Factors

Several components of diet and behavior have been suggested as risk factors for colorectal cancer, with various levels of consistency.[48, 49, 50] Modifying these lifestyle factors may work toward prevention of hereditary nonpolyposis colorectal cancer (HNPCC). Experts differ on the interpretation of the evidence for some of these components. Little is known about whether these same factors are protective in people with a genetically increased risk of colorectal cancer.

In one case-control study, lack of physical activity, low intake of high-energy foods, and low intake of vegetables contributed significantly to an increased cancer risk in people with no family history of colorectal cancer; however, in those with a family history of colorectal cancer, activity level and diet were not related to cancer risk, despite adequate statistical power.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Juan Carlos Munoz, MD  Associate Professor of Medicine and Director of the Endoscopy Unit, Division of Gastroenterology, University of Florida College of Medicine at Jacksonville

Juan Carlos Munoz, MD is a member of the following medical societies: American College of Physicians, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Coauthor(s)

Louis R Lambiase, MD, MHA  Professor of Medicine, University of Tennessee College of Medicine Chattanooga; Chief, Division of Gastroenterology, University of Tennessee Chattanooga Unit; Assistant Dean for Clinical Affairs, University of Tennessee College of Medicine Chattanooga

Louis R Lambiase, MD, MHA is a member of the following medical societies: American Gastroenterological Association, American Pancreatic Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Simmy Bank, MD  Chair, Professor, Department of Internal Medicine, Division of Gastroenterology, Long Island Jewish Hospital, Albert Einstein College of Medicine

Disclosure: Nothing to disclose.

Alex J Mechaber, MD, FACP  Senior Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine

Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD  Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

References

  1. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med. Mar 30 1995;332(13):839-47. [Medline]. [Full Text].

  2. Lothe RA, Peltomaki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. Dec 15 1993;53(24):5849-52. [Medline].

  3. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst. Aug 2 1995;87(15):1114-25. [Medline].

  4. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. Jan 1997;6(1):105-10. [Medline]. [Full Text].

  5. American Cancer Society. Cancer facts & figures 2008. Atlanta, Ga: American Cancer Society; 2008. Available at http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_and_Figures_2008.asp?from=fast. Accessed February 13, 2009.

  6. Levin B, Lieberman DA, McFarland B, et al, for the American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. May 2008;134(5):1570-95. [Medline].

  7. Giraldez MD, Balaguer F, Bujanda L, Cuatrecasas M, Munoz J, Alonso-Espinaco V. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res. Oct 5 2010;[Medline].

  8. American Cancer Society. Available at http://www.cancer.org/docroot/home/index.asp. Accessed February 20, 2009.

  9. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. Dec 3 1997;89(23):1758-62. [Medline]. [Full Text].

  10. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. Jul 2008;10(4):301-7. [Medline]. [Full Text].

  11. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. Jul 19 2011;155(2):69-79. [Medline].

  12. Weissman SM, Bellcross C, Bittner CC, Freivogel ME, Haidle JL, Kaurah P. Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome-A Review. J Genet Couns. Oct 8 2010;[Medline].

  13. Vasen HF, Nagengast FM, Griffioen G, et al, for The Work Group 'Hereditary non-polyposis- colon-rectum cancers'. [Periodic colonoscopic examinations of persons with a positive family history for colorectal cancer] [Dutch]. Ned Tijdschr Geneeskd. Jun 5 1999;143(23):1211-4. [Medline].

  14. Smith RA, von Eschenbach AC, Wender R, et al, for the ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin. Jan-Feb 2001;51(1):38-75; quiz 77-80. [Medline]. [Full Text].

  15. Winawer S, Fletcher R, Rex D, et al, for the Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. Feb 2003;124(2):544-60. [Medline].

  16. Love RR, Morrissey JF. Colonoscopy in asymptomatic individuals with a family history of colorectal cancer. Arch Intern Med. Nov 1984;144(11):2209-11. [Medline].

  17. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. May 1991;34(5):424-5. [Medline].

  18. Mecklin JP, Jarvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 Finnish kindreds. Gastroenterology. Feb 1986;90(2):328-33. [Medline].

  19. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. Sep 27 2006;296(12):1507-17. [Medline].

  20. Ramsoekh D, Wagner A, van Leerdam ME, et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract. Dec 23 2009;7(1):17. [Medline]. [Full Text].

  21. Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. Jun 8 2011;305(22):2304-10. [Medline].

  22. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. Aug 1 2006;66(15):7810-7. [Medline]. [Full Text].

  23. Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. May 2002;37(5):574-7. [Medline].

  24. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by The International Collaborative Group on HNPCC. Gastroenterology. Jun 1999;116(6):1453-6. [Medline].

  25. Ramsey SD. Screening for the Lynch syndrome. N Engl J Med. Aug 4 2005;353(5):524-5; author reply 524-5. [Medline].

  26. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. May 5 2005;352(18):1851-60. [Medline]. [Full Text].

  27. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. Feb 1 1993;71(3):677-85. [Medline].

  28. Bliss CM Jr, Schroy PC 3rd. Endoscopic diagnosis and management of hereditary nonpolyposis colorectal cancer. Curr Opin Gastroenterol. Sep 2004;20(5):468-73. [Medline].

  29. Foster JH. Survival after liver resection for cancer. Cancer. Sep 1970;26(3):493-502. [Medline].

  30. Exelby PR, Filler RM, Grosfeld JL. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey--1974. J Pediatr Surg. Jun 1975;10(3):329-37. [Medline].

  31. Weinberger JM, Cohen Z, Berk T. Polyposis coli preceded by hepatocellular carcinoma: report of a case. Dis Colon Rectum. May-Jun 1981;24(4):296-300. [Medline].

  32. Locker G, ed. Colorectal cancer: extracolonic manifestations in HNPCC. Updated April 7, 2006. Chicago Center for Jewish Genetic Disorders. Available at http://www.jewishgeneticscenter.org/professional/colorectal/#HNPCC. Accessed February 20, 2009.

  33. Lanspa SJ, Jenkins JX, Cavalieri RJ, et al. Surveillance in Lynch syndrome: how aggressive?. Am J Gastroenterol. Nov 1994;89(11):1978-80. [Medline].

  34. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum. Dec 2002;45(12):1588-94. [Medline].

  35. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med. Nov 15 1998;129(10):787-96. [Medline]. [Full Text].

  36. Stupart DA, Goldberg PA, Baigrie RJ, Algar U, Ramesar R. Surgery for colonic cancer in HNPCC: Total versus segmental colectomy. Colorectal Dis. Oct 22 2010;[Medline].

  37. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. Mar 2002;3(3):166-74. [Medline].

  38. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. Feb 2002;8(2):314-46. [Medline]. [Full Text].

  39. DuBois RN, Smalley WE. Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol. Dec 1996;31(6):898-906. [Medline].

  40. Sinicrope FA, Half E, Morris JS, et al, for the Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. Jun 2004;13(6):920-7. [Medline]. [Full Text].

  41. Markowitz SD. Aspirin and colon cancer--targeting prevention?. N Engl J Med. May 24 2007;356(21):2195-8. [Medline].

  42. Cole BF, Baron JA, Sandler RS, et al, for the Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. Jun 6 2007;297(21):2351-9. [Medline]. [Full Text].

  43. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med. Oct 1 1998;129(7):517-24. [Medline]. [Full Text].

  44. Baron JA, Beach M, Mandel JS, et al, for The Calcium Polyp Prevention Study Group. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med. Jan 14 1999;340(2):101-7. [Medline]. [Full Text].

  45. Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst. Dec 3 2003;95(23):1765-71. [Medline]. [Full Text].

  46. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst. Mar 20 2002;94(6):437-46. [Medline]. [Full Text].

  47. Estrogen linked to colon cancer protection. February 9, 2004. EndoNurse.com. Available at http://www.endonurse.com/hotnews/42h9888.html. Accessed February 13, 2009.

  48. Slattery ML, Caan BJ, Potter JD, et al. Dietary energy sources and colon cancer risk. Am J Epidemiol. Feb 1 1997;145(3):199-210. [Medline]. [Full Text].

  49. Colangelo LA, Gapstur SM, Gann PH, Dyer AR. Cigarette smoking and colorectal carcinoma mortality in a cohort with long-term follow-up. Cancer. Jan 15 2004;100(2):288-93. [Medline]. [Full Text].

  50. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer. Feb 2 2001;84(3):417-22. [Medline]. [Full Text].

  51. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. Jun 2010;138(6):2073-2087.e3. [Medline].

  52. Brentnall T, Nguyen T, Mealiffe M,Grady WM, Wong E. Colon cancer screening. Available at http://www.uwgi.org/guidelines/ch_08/ch08txt.htm. Accessed February 20, 2009.

  53. Rustgi AK. Mechanisms and epidemiology of colon cancer (PowerPoint presentation). Available at www.fda.gov/ohrms/dockets/ac/02/slides/3845s1_01_rustgi.ppt. Accessed February 20. 2009.

  54. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. Dec 11 1992;258(5089):1795-8. [Medline].

  55. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. Dec 20 1995;64(6):430-3. [Medline].

  56. Houlston RS, Murday V, Harocopos C, Williams CB, Slack J. Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. BMJ. Aug 18-25 1990;301(6748):366-8. [Medline]. [Full Text].

  57. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. Mar 17 1994;368(6468):258-61. [Medline].

  58. Calistri D, Presciuttini S, Buonsanti G, et al. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Int J Cancer. Jan 20 2000;89(1):87-91. [Medline]. [Full Text].

  59. Church JM. Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med. Dec 1996;28(6):479-82. [Medline].

  60. Cummings JH, Bingham SA. Diet and the prevention of cancer. BMJ. Dec 12 1998;317(7173):1636-40. [Medline]. [Full Text].

  61. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Philadelphia, Pa: Saunders Elsevier; 2006.

  62. Heiskanen I, Jarvinen HJ. Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Int J Colorectal Dis. 1997;12(1):9-13. [Medline].

  63. Hendriks YM, de Jong AE, Morreau H, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin. Jul-Aug 2006;56(4):213-25. [Medline]. [Full Text].

  64. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. Jan 2000;156(1):29-35. [Medline]. [Full Text].

  65. Lanspa SJ, Jenkins JX, Watson P, et al. Natural history of at-risk Lynch syndrome family members with respect to adenomas. Nebr Med J. Nov 1992;77(11):310-3. [Medline].

  66. Lin KM, Shashidharan M, Ternent CA, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. Apr 1998;41(4):428-33. [Medline].

  67. [Best Evidence] Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. Sep 27 2006;296(12):1507-17. [Medline]. [Full Text].

  68. Locker G, ed. Colorectal cancer: Muir-Torre and Turcot syndrome. Updated April 7, 2006. Chicago Center for Jewish Genetic Disorders. Available at http://www.jewishgeneticscenter.org/professional/colorectal/#muir. Accessed February 20, 2009.

  69. Lynch HT. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers?. Dis Colon Rectum. Jan 1996;39(1):109-10. [Medline].

  70. Lynch HT, Boland CR, Gong G, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet. Apr 2006;14(4):390-402. [Medline]. [Full Text].

  71. Lynch HT, Krush AJ. Cancer family "G" revisited: 1895-1970. Cancer. Jun 1971;27(6):1505-11. [Medline].

  72. Lynch HT, Riley BD, Weissman SM, et al. Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer. Jan 1 2004;100(1):53-64. [Medline]. [Full Text].

  73. Mizoguchi T, Yamada K, Furukawa T, et al. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J Natl Cancer Inst. Nov 7 1990;82(21):1679-83. [Medline].

  74. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum. Nov 1993;36(11):1059-62. [Medline].

  75. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. Jan 19 2006;354(3):261-9. [Medline]. [Full Text].

  76. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. Feb 18 2004;96(4):261-8. [Medline]. [Full Text].

  77. Winn RJ, McClure J. NCCN Clinical Practice Guidelinesin Oncology - v.1.2003. Available at http://www.nccn.org/professionals/physician_gls/PDF/introduction.pdf. Accessed February 20, 2009.

  78. Burn J, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;61049-0.

 
Previous
Next
 
Example of an autosomal dominant pedigree.
Diagnostic approach for patients with colorectal tumors.
Table 1. Seven different genes are known to be associated with HNPCC, and all of them are involved with DNA mismatch repair, identified with the frequencies below.
Mismatch Excision Repaired MMRChromosome LocationFrequency of HNPCC Cases
MSH22p1645-50%
MLH13p22.3/A>20%
MSH62p1610%
PMS27p22.11%
PMS12q32.2Rare
MSH35q14.1Rare
EXO11q43Rare
Other genes not yet discovered20-25%
Table 2. Incidence of different types of cancers between individuals with Lynch syndrome and those in the general population.
Type of CancerGeneral Population Risk (by age 70 y)Lynch Syndrome Risk (by age 70 y)
Endometrial1.5%30-40%
Ovarian1%9-12%
Upper Urinary TractLess than 1%4-10%
StomachLess than 1%13% (higher in Asians)
Small BowelLess than 1%1-3%
BrainLess than 1%1-4%
Biliary TractLess than 1%1-5%
Table 3. IHC staining findings.
MMR MutationsProtein Staining
MLH1MSH2MSH6PMS2
MLH1-++-
MSH2+--+
MSH6++-+
PMS2+++-
Table 4. Netherlands surveillance protocol for carriers of an MMR-gene mutation.
SurveillanceMLH1, MSH2, MSH6 (males)MSHG (females)
ColonColonoscopy, every 1-2 years, starting at age 20-25 yearsColonoscopy, every 1-2 years, starting at age 30 years
EndometriumUltrasonography and CA-125, every 1-2 years, starting at age 30-35 yearsUltrasonography and CA-125, every 1-2 years, starting at age 30-35 years; consider hysterectomy after age 50 years
Upper Urinary TractUrine cytology analysis, every 1-2 years, starting at age 30-35 years, if it occurs 2 or more times in a familyUrine cytology analysis, every 1-2 years, starting at age 30-35 years, if it occurs 2 or more times in a family
StomachGastroscopy every 1-2 years, starting at age 30-35 years, if it occurs 2 or more times in a familyGastroscopy every 1-2 years, starting at age 30-35 years, if it occurs 2 or more times in a family
Table 5. Dukes classification.
StageTumorNodeMetastasisDukes
Stage 1T1N0M0Dukes A
T2N0M0
Stage IIT3N0M0Dukes B
T4N0M0
Stage IIIAny TN1M0Dukes C
Any TN2, N3Mo
Stage IVAny TAny NM1Dukes D
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.